Hainan Poly Pharm Co Ltd (300630) - Total Liabilities
Based on the latest financial reports, Hainan Poly Pharm Co Ltd (300630) has total liabilities worth CN¥3.45 Billion CNY (≈ $504.18 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Hainan Poly Pharm Co Ltd (300630) net asset momentum to track the company's year-over-year net asset growth rate.
Hainan Poly Pharm Co Ltd - Total Liabilities Trend (2016–2023)
This chart illustrates how Hainan Poly Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300630 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Hainan Poly Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hainan Poly Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Onano Industrial Corp
TW:6405
|
Taiwan | NT$12.97 Million |
|
CMG Pharmaceutical Co. Ltd
KQ:058820
|
Korea | ₩104.41 Billion |
|
Mukka Proteins Limited
NSE:MUKKA
|
India | Rs7.77 Billion |
|
Tridomain Performance Materials PT
JK:TDPM
|
Indonesia | Rp128.03 Million |
|
Lokesh Machines Limited
NSE:LOKESHMACH
|
India | Rs2.33 Billion |
|
Rama Steel Tubes Limited
NSE:RAMASTEEL
|
India | Rs4.08 Billion |
|
Intellicheck Mobilisa Inc
NASDAQ:IDN
|
USA | $3.78 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down Hainan Poly Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300630 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Poly Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Poly Pharm Co Ltd (2016–2023)
The table below shows the annual total liabilities of Hainan Poly Pharm Co Ltd from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | CN¥3.38 Billion ≈ $494.67 Million |
+7.10% |
| 2022-12-31 | CN¥3.16 Billion ≈ $461.90 Million |
+48.86% |
| 2021-12-31 | CN¥2.12 Billion ≈ $310.29 Million |
+108.54% |
| 2020-12-31 | CN¥1.02 Billion ≈ $148.80 Million |
+77.04% |
| 2019-12-31 | CN¥574.37 Million ≈ $84.05 Million |
+154.48% |
| 2018-12-31 | CN¥225.70 Million ≈ $33.03 Million |
+47.37% |
| 2017-12-31 | CN¥153.16 Million ≈ $22.41 Million |
+15.50% |
| 2016-12-31 | CN¥132.60 Million ≈ $19.40 Million |
-- |
About Hainan Poly Pharm Co Ltd
Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company's dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, exc… Read more